Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

ABSTRACT: Tumor molecular profiling is a fundamental component of precision oncology, enabling the identification of genomic alterations in genes and pathways that can be targeted therapeutically. The existence of recurrent targetable alterations across distinct histologically defined tumor types, coupled with an expanding portfolio of molecularly targeted therapies, demands flexible and comprehensive approaches to profile clinically relevant genes across the full spectrum of cancers. We established a large-scale, prospective clinical sequencing initiative using a comprehensive assay, MSK-IMPACT, through which we have compiled tumor and matched normal sequence data from a unique cohort of more than 10,000 patients with advanced cancer and available pathological and clinical annotations. Using these

SUBMITTER: Zehir A 

PROVIDER: S-EPMC5461196 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature